Abstract: OBJECTIVE To introduce advances in research of a new antibiotics Dalbavancin. METHODS Based on the correlative materials of recent 10 year searched from the data base of Google Scholar and Science Direct, the antibacterial mechanism, the antibacterial activity, the pharmacokinetics, the pharmacodynamics and drug safety of Dalbavancin had been briefly summarized overlaying multiple perspectives. RESULTS Dalbavancin is a concentration-dependent antibiotic of glycopeptides. The antibacterial activity in vivo and vitro of Dalbavancin with low bacteria resistance mutation rate, mild untoward effect and low drug toxicity(MIC50=0.06 mg·L^-1) is obviously superior to vancomycin(MIC50=1 mg·L^-1) and teicoplanin(MIC50=0.5 mg·L^-1); The clinical pharmacokinetics of Dalbavancin indicated the potential of administration once-weekly and the effective treatment concentration is 20 mg·L^-1. CONCLUSION Dalbavancin is a lower bacteria resistance mutation rate, moderate adverse reactions and lower drug toxicity new antibiotics with most application value in phase Ⅲ clinical studies.